undamentalytics Newsletter

Laplume Joseph W: insider trades

Officer at Charles River Laboratories. No open-market purchases and 25 sales not made under a pre-set plan, reported from March 12, 2019 to January 20, 2026.

What happened after Laplume Joseph W’s sales?

After their sales, the shares moved −11.2% against the index over 12 months on average (a negative figure means selling was the right call); 83% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Laplume Joseph W: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 25 −3.0% −2.4% 60% 8 −1.58 0.16 No reliable evidence
Sales, 12 months after the report 24 −11.2% −17.4% 83% 7 −0.89 0.41 No reliable evidence
Sales, 12 months after the trade 25 −7.7% −12.3% 68% 7 −0.70 0.51 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Charles River Laboratories CRL EVP, Corp Strategy & Develop025March 12, 2019January 20, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
January 20, 2026August 22, 2025 CRL Sale $65,488 −22.6%not yet+63.9%
August 20, 2025August 18, 2025 CRL Sale $126,080 0.0%+71.7%+63.9%
August 8, 2025August 7, 2025 CRL Sale $60,016 +7.0%+68.1%+61.3%
May 15, 2025May 13, 2025 CRL Sale $72,705 +2.8%−16.8%−18.5%
February 21, 2025February 20, 2025 CRL Sale $715,000 −17.1%−19.2%−12.3%
August 12, 2024August 8, 2024 CRL Sale $354,861 −2.4%−43.2%−47.0%
May 14, 2024May 10, 2024 CRL Sale $295,969 −17.8%−52.9%−53.3%
February 20, 2024February 15, 2024 CRL Sale $200,223 −15.3%−50.9%−56.4%
December 1, 2023November 30, 2023 CRL Sale $365,800 +19.2%−35.5%−31.9%
November 13, 2023November 9, 2023 CRL Sale $1,583,522 +25.3%−23.6%−9.7%
August 14, 2023August 10, 2023 CRL Sale $151,564 −18.8%−30.4%−32.0%
May 16, 2023May 15, 2023 CRL Sale $65,685 −3.9%−16.7%−9.2%
May 15, 2023May 12, 2023 CRL Sale $185,116 −0.2%−11.3%−7.2%
December 5, 2022December 1, 2022 CRL Sale $1,437,194 +1.9%−22.2%−25.2%
November 7, 2022November 4, 2022 CRL Sale $115,536 +5.2%−39.2%−35.0%
August 8, 2022August 5, 2022 CRL Sale $45,226 +12.6%−8.7%−18.0%
February 24, 2022February 23, 2022 CRL Sale $115,636 −15.1%−17.9%−17.9%
February 23, 2022February 18, 2022 CRL Sale $448,696 −16.0%−17.9%−18.7%
August 10, 2021August 6, 2021 CRL Sale $1,488,173 −9.6%−39.3%−40.6%
February 26, 2021February 25, 2021 CRL Sale $2,460,592 +8.5%−13.0%−10.0%
November 5, 2020November 4, 2020 CRL Sale $1,686,636 −1.1%+13.3%+14.3%
May 19, 2020May 15, 2020 CRL Sale $2,655,320 +8.2%+43.7%+42.6%
March 12, 2019March 8, 2019 CRL Sale $796,339 −9.1%−2.2%+1.7%
March 12, 2019March 8, 2019 CRL Sale $759,896 −9.1%−2.2%+1.7%
March 12, 2019March 8, 2019 CRL Sale $230,296 −9.1%−2.2%+1.7%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Laplume Joseph W traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.